From what 17 stock analysts predict, the share price for Danaher Corp (DHR) might increase by 16.38% in the next year. This is based on a 12-month average estimation for DHR. Price targets go from $236 to $315. The majority of stock analysts believe DHR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
DHR is a stock in Healthcare which has been forecasted to be worth $288.34 as an average. On the higher end, the forecast price is $315 USD by from Keybanc and on the lower end DHR is forecasted to be $236 by from .
These are the latest 20 analyst ratings of DHR.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Doug Schenkel Wolfe Research | Outperform | $285 | Upgrade | Oct 31, 2024 |
Dan Leonard UBS | Buy | $305 | Maintains | Oct 23, 2024 |
Catherine Schulte Baird | Outperform | $277 | Maintains | Oct 23, 2024 |
Daniel Arias Stifel | Hold | $265 | Maintains | Oct 23, 2024 |
Andrew Cooper Raymond James | Outperform | $300 | Maintains | Oct 23, 2024 |
Luke Sergott Barclays | Equal-Weight | $275 | Maintains | Oct 23, 2024 |
Paul Knight Keybanc | Overweight | $310 | Maintains | Oct 23, 2024 |
Dan Brennan TD Cowen | Buy | $315 | Maintains | Oct 23, 2024 |
Conor McNamara RBC Capital | Outperform | $311 | Maintains | Oct 23, 2024 |
Jacob Johnson Stephens & Co. | Overweight | $315 | Reiterates | Oct 23, 2024 |
Jacob Johnson Stephens & Co. | Overweight | $315 | Initiates | Oct 1, 2024 |
Vijay Kumar Evercore ISI Group | Outperform | $278 | Maintains | Oct 1, 2024 |
Conor McNamara RBC Capital | Outperform | $300 | Reiterates | Sep 6, 2024 |
Brandon Couillard Wells Fargo | Equal-Weight | $280 | Initiates | Aug 27, 2024 |
Leerink Partners | Outperform | $280 | Maintains | Jul 24, 2024 |
Daniel Arias Stifel | Hold | $250 | Maintains | Jul 24, 2024 |
Luke Sergott Barclays | Equal-Weight | $285 | Maintains | Jul 24, 2024 |
Matthew Sykes Goldman Sachs | Neutral | $250 | Maintains | Jul 24, 2024 |
Catherine Schulte Baird | Outperform | $278 | Maintains | Jul 24, 2024 |
Conor McNamara RBC Capital | Outperform | $300 | Maintains | Jul 24, 2024 |
When did it IPO
1987
Staff Count
61,000
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Rainer M. Blair
Market Cap
$180.62B
In 2023, DHR generated $23.89B in revenue, which was a decrease of -10.33% from the previous year. This can be seen as a signal that DHR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Danaher's (DHR) international revenue trends may affect Wall Street forecasts and the future performance of its stock, suggesting potential investment considerations.
Why It Matters - Danaher's international revenue patterns influence Wall Street forecasts, affecting stock performance expectations and potential volatility in the market.
Summary - Seven companies are generating steady profits, which are being converted into increasing passive income streams for investors.
Why It Matters - Rising passive income streams signal strong financial health and stability, making these companies attractive for long-term investment and potential capital appreciation.
Summary - Danaher reported Q3 earnings with cautious optimism, indicating a return to growth. However, management refrained from providing specific forecasts, suggesting potential uncertainties ahead.
Why It Matters - Danaher's cautious Q3 earnings signal potential volatility, impacting growth forecasts and investor sentiment, indicating the need for careful assessment of future performance.
Summary - Danaher exceeded Q3 profit expectations due to strong demand in diagnostics and bioprocessing, with notable growth in its molecular testing unit.
Why It Matters - Danaher's strong Q3 performance signals robust demand in key sectors, potentially driving stock price appreciation and enhancing investor confidence in the company's growth trajectory.
Summary - Danaher Corp (DHR) reported Q3 sales of $5.79 billion, a 3% increase year-over-year, surpassing the consensus estimate of $5.59 billion.
Why It Matters - Danaher Corp's stronger-than-expected sales growth signals robust demand and operational efficiency, potentially boosting investor confidence and stock performance.
Summary - Danaher Corporation (NYSE:DHR) held its Q3 2024 earnings call on October 22, 2024, with key executives discussing financial results and engaging with analysts from various institutions.
Why It Matters - Danaher's Q3 earnings call provides insights into financial performance and future guidance, influencing stock valuation and investment decisions. Analyst questions may reveal market sentiment and strategic direction.